Journal of Medicinal Chemistry · 2006 · 44 citations · 25 references
MedicineMedicinal ChemistryOncologyCancer PharmacologyDrug DeliveryMolecular OncologyBrain Targeted DeliveryPrimary Brain Tumor RadiotherapyBiological Evaluation ReportBoron ChemistryGeometric IsomersNeutron Capture ProcessesNeutron IrradiationNeutron Irradiation EffectsNeutron-capture Reactions
3-[5-{2-(2,3-Dihydroxyprop-1-yl)-o-carboran-1-yl}pentan-1-yl]thymidine (compound 1, N5-2OH) belongs to a novel class of boron delivery agents for neutron capture therapy, which was designated 3-carboranylthymidine analogue (3CTAs). Two shorter and more convenient synthetic routes were developed for the synthesis of 1 in the 10B-enriched form, which is necessary for its preclinical and clinical evaluation in neutron irradiation studies. For more insight on structure-activity relationships, various stereochemical and geometrical isomers of 1 were synthesized and their specificities as substrate for human thymidine kinase 1 (hTK1) were evaluated. A computational model for the binding of various isomers of 1 to the active site of hTK1 was developed. Preliminary studies carried out in F98 glioma bearing rats that had received a 10B-enriched form of 1 followed by neutron irradiation demonstrated a significant prolongation in survival times compared to control animals, suggesting that further studies are warranted to evaluate the therapeutic potential of 1.
25
Virginia A. Elrod, Kenneth S. Johnson, Kenneth H. Coale · Analytical Chemistry · 1991 · 189 citations